These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28718698)

  • 1. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia
    Rausch CR; Marini BL; Benitez LL; Elias A; Burke PW; Bixby D; Perissinotti AJ
    Leuk Lymphoma; 2018 Mar; 59(3):617-624. PubMed ID: 28718698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
    Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
    Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
    Christ TN; Stock W; Knoebel RW
    J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ribera JM; Morgades M; Montesinos P; Martino R; Barba P; Soria B; Bermúdez A; Moreno MJ; González-Campos J; Vives S; Gil C; Abella E; Guàrdia R; Martínez-Carballeira D; Martínez-Sánchez P; Amigo ML; Mercadal S; Serrano A; López-Martínez A; Vall-Llovera F; Sánchez-Sánchez MJ; Peñarrubia MJ; Calbacho M; Méndez JA; Bergua J; Cladera A; Tormo M; García-Belmonte D; Feliu E; Ciudad J; Orfao A;
    Leuk Lymphoma; 2018 Jul; 59(7):1634-1643. PubMed ID: 29165013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
    Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
    Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
    Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
    Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
    Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peg-asparaginase for acute lymphoblastic leukemia.
    Rytting M
    Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.
    Patel B; Kirkwood AA; Dey A; Marks DI; McMillan AK; Menne TF; Micklewright L; Patrick P; Purnell S; Rowntree CJ; Smith P; Fielding AK
    Leukemia; 2017 Jan; 31(1):58-64. PubMed ID: 27480385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
    Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
    J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Outcome of a Pediatric-Inspired Protocol for High-Risk Adolescent and Young Adult Acute Lymphoblastic Leukemia Patients Using Peg-Asparaginase and Escalating Dose of Methotrexate: Tolerability and Outcome.
    Hanbali A; Kotb A; El Fakih R; Alfraih F; Ahmed SO; Shaheen M; Hashmi S; Alhayli S; Alahmari A; Riash MA; Rasheed W; Alzahrani H; Alsharif F; Chaudhri N; Almohareb F; Aljurf M
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):670-677. PubMed ID: 31377206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
    Blackman A; Boutin A; Shimanovsky A; Baker WJ; Forcello N
    J Oncol Pharm Pract; 2018 Jul; 24(5):393-397. PubMed ID: 28523950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia.
    Trang E; Ngo D; Chen J; Aldoss I; Salhotra A; Pullarkat V
    Leuk Lymphoma; 2020 Dec; 61(13):3161-3164. PubMed ID: 32787645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole-induced hepatotoxicity following the administration of PEG-asparaginase: Case report.
    Gallant R; Bonney P; Peek L; Yu Z; Crawford D
    Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27748018
    [No Abstract]   [Full Text] [Related]  

  • 18. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
    Cooperation Group of Phase II Clinical Trial of PEG-Asp
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
    Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
    Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.